The Donald Trump administration has unveiled a sweeping tariff policy targeting imported pharmaceutical products, introducing penalties of up to 100% for drugmakers that fail to align with new U.S. pricing and manufacturing expectations.
The policy, announced Thursday, marks a significant escalation in the administration’s broader push to secure domestic drug production and lower prescription costs. Officials say the move is designed to strengthen supply chain resilience while pressuring global pharmaceutical companies to invest in U.S.-based manufacturing.
“We need to make sure that our drug supply is protected, secure and domestic,” a senior administration official, who declined to be named, told reporters on Thursday. “That is what we’re doing.”
Under the new framework, patented medications and their active ingredients will face a steep 100% tariff unless manufacturers take steps to localize production or negotiate pricing agreements with federal regulators.
Companies that commit to shifting production to the United States will initially face a reduced 20% tariff, which will gradually rise to 100% over four years if domestic facilities are not completed. To qualify for exemptions, drugmakers must finalize U.S. manufacturing projects by January 2029 or actively negotiate pricing deals with the Department of Health and Human Services.
Large pharmaceutical firms have been given a 120-day window before the highest tariff rate takes effect, while smaller companies often dependent on contract manufacturing will have 180 days to comply.
Not all countries will be affected equally. Nations with broader trade agreements with the U.S., including parts of Europe and Asia, will see reduced pharmaceutical tariffs. Imports from the European Union, Japan, South Korea, and Switzerland will face a 15% levy, while the United Kingdom will see a lower 10% rate.
“Those countries, the production can stay in those countries because they’ve made a bigger trade deal with America,” the official said.
Certain categories including genetic therapies, biosimilars, and treatments for rare diseases, are currently excluded from the tariff regime, though officials say these exemptions will be reviewed within a year. Specialty pharmaceutical products tied to urgent public health needs may also avoid levies under specific conditions.
The policy follows a Commerce Department investigation that identified some pharmaceutical imports as potential national security risks. It also builds on earlier efforts to tie U.S. drug prices to lower international benchmarks through the administration’s “most favored nation” strategy.
Major drugmakers such as Eli Lilly, Pfizer, and Novo Nordisk have already reached agreements with the administration to reduce prices, securing temporary exemptions from tariffs. Officials say 13 companies have signed deals so far, with negotiations ongoing with several others.
The administration claims the tariff strategy has already driven significant investment into U.S. manufacturing, with approximately $400 billion in commitments from pharmaceutical companies during Trump’s term.
These developments come amid a long-term decline in domestic drug production, which policymakers argue has left the U.S. vulnerable to supply disruptions.
In a parallel move, the administration revised tariff rules on industrial metals, including steel, aluminum, and copper. While the base tariff remains at 50%, it will now apply to the full value of imported raw materials rather than just the metal content.
Finished goods containing more than 15% of these metals will face a 25% tariff on their total value, replacing the previous system that only taxed the metal portion. Products with less than 15% metal content will be exempt.
Officials say the changes are intended to prevent foreign exporters from undervaluing goods to minimize tariff obligations. However, independent analysts suggest the revised structure could modestly increase costs for importers.
According to the Committee for a Responsible Federal Budget, the updated tariff framework could generate an additional $70 billion in federal revenue over the next decade.
